Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response

Authors: Camacho R, Clotet B, De Luca A, Geretti AM, Grossman Z, Kaiser R, Prosperi M, Schmit JC, Sönnerborg A, Torti C, Van Wijngaerden E, Vercauteren J, Zazzi M, Beheydt G, Imbrechts S, Libin P, Vandamme AM, Van Laethem K
Journal: PLoS One
Link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0061436

Clinically evaluating genotypic interpretation systems is essential to provide optimal guidance in designing potent individualized HIV-regimens. This study aimed at investigating the ability of the latest Rega algorithm to predict virological response on a short and longer period.
Read More

HIV-1 subtype is an independent predictor of reverse transcriptase mutation k65r in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

Authors: Abecasis AB, Camacho RJ, Clotet B, De Luca A, Grossman Z, Schülter E, Snoeck J, Sönnerborg A, Struck D, Theys K, Torti C, Vandamme AM, Vercauteren J, Zazzi M
Journal: Antimicrobial Agents and Chemotherapy
Link: http://www.ncbi.nlm.nih.gov/pubmed/23183438

Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.
Read More

Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving com- bination therapy including tenofovir

Authors: Abecasis AB, Abreu R, Aguas MJ, Aldir I, Aleixo MJ, Amaro G, Antunes F, Borges F, Botas J, Branco T, Caixas U, Camacho RJ, Diniz A, Doroana M, Duque L, Faria D, Faria N, Faria T, Fonseca P, Germano I, Gomes F, Guerreiro C, Jesus MB, Mansinho K, Mineiro A, Miranda AC, Narciso J, Neves I, Nina J, Pinheiro S, Pinto IV, Proença P, Reis AP, Roxo F, Sá J, Santos C, Snoeck J, Tavares L, Teófilo E, Theys K, Valadas E, Vandamme AM, Ventura F, Vera J, Vercauteren J
Journal: Journal of Antimicrobial Chemotherapy
Link: http://www.ncbi.nlm.nih.gov/pubmed/23027713

The use of tenofovir is highly associated with the emergence of mutation K65R, which confers broad resistance to nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs), especially when tenofovir is combined with other NRTIs also selecting for K65R. Although recent HIV-1 treatment guidelines discouraging these combinations resulted in reduced K65R selection with tenofovir, updated information on the impact of currently recommended regimens on the population selection rate of K65R is presently lacking.
Read More

HIV-1 sub- type distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics

Authors: Abecasis AB, Albert J, Åsjö B, Balotta C, Beshkov D, Boucher CA, Camacho RJ, Clotet B, De Gascun C, Griskevicius A, Grossman Z, Hamouda O, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Kücherer C, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Struck D, Theys K, Van de Vijver DMC, Vandamme AM, Vercauteren J, Wensing AMJ
Publication Year: 2013
Journal: Retrovirology
Link: http://www.retrovirology.com/content/10/1/7

Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes.
Read More

Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic

Authors: Albert J, Balotta C, Boucher C, De Munter P, Derdelinckx I, Ferreira F, Gomez-Lopez A, Khouri R, Kostrikis LG, Kücherer C, Li G, Littsola K, Nielsen C, Paredes R, Pineda-Peña AC, Schrooten Y, Stanojevic M, Trovão NS, Van Laethem K, Van Ranst M, Van Wijngaerden E, Vandamme AM, Vercauteren J, Vinken L, Wensing A
Publication Year: 2014
Journal: PLoS One
Link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0101738

We aimed to study epidemic trends and predictors for transmitted drug resistance (TDR) in our region, its clinical impact and its association with transmission clusters. We included 778 patients from the AIDS Reference Center in Leuven (Belgium) diagnosed from 1998 to 2012. Resistance testing was performed using population-based sequencing and TDR was estimated using the WHO-2009 surveillance list.
Read More

Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response

HIV-1 subtype is an independent predictor of reverse transcriptase mutation k65r in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving com- bination therapy including tenofovir

HIV-1 sub- type distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics

Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic

About GHTM

Contacts

Map